Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib in Combination With Azacitidine for MDS/MPN and CNL
NCT07071155Phase 1Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mivavotinib in myelodysplastic/myeloproliferative neoplasm (MDS/MPN), chronic neutrophilic leukemia (CNL) and chronic myelomonocytic leukemia (CMML), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Complete Response at 24 weeks, Partial Response at 24 weeks and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
mivavotinib
03
Conditions
myelodysplastic/myeloproliferative neoplasm (MDS/MPN)chronic neutrophilic leukemia (CNL)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT07071155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071155.